Alterity Therapeutics (PRAN) Stock Price, News & Analysis

Company Overview

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Key Stats

• Today's Range: $4.97 to $5.04
• 50-Day Range: $0.95 to $2.06
• 52-Week Range: $1.09 to $2.91
• Volume: 3,639 shs
• Average Volume: 130,956 shs
• Market Capitalization: $44.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PRAN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Alterity Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include Meta Platforms (META), Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), Intercept Pharmaceuticals (ICPT), Rigel Pharmaceuticals (RIGL), Arena Pharmaceuticals (ARNA) and Conatus Pharmaceuticals (CNAT).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PRAN
• CIK: 1131343
• Web: www.pranabio.com
• Phone: (139) 349-4906
• Fax: N/A
• Employees: 14
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.37
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $150 thousand
• Price / Sales: 296.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.40 per share
• Price / Book: 3.57

Miscellaneous

• Outstanding Shares: 8,900,000
• Free Float: N/A
• Market Cap: $44.50 million
• Optionable: Not Optionable
• Beta: 1.05